drugset / Trial / NCT04331132

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction

NCT04331132

RandomizedParallel-groupOpen-labelTreatment

Summary

Renal dysfunction, which comprises 10%-40% of acute heart failure patients (AHF), plays an important role in diuretic resistance mechanism. DR-AHF was designed to demonstrate the effectiveness of early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in acute heart failure patients with renal dysfunction and clinical evidence of loop diuretic resistance.

Timeline

Start
2021-12-01
Primary completion
2023-06-30
Completion
2023-07-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tolvaptan Small molecule 15 mg

Indications